Annovis Bio Inc. (NYSE: ANVS) Gets FDA Clearance for Buntanetap Pivotal Phase 3 Trials, Market Enthusiasm Highlighted in GuruFocus Article
Financial research platform GuruFocus underlines Annovis’ unique approach to tackling neurodegenerative conditions such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The FDA's decision to allow the company to go to Phase 3, points to the fact that lead drug candidate buntanetap may be an effective treatment for AD, one of the most critical diseases in an aging society. Buntanetap has been shown to significantly improve cognition in early AD patients, both by itself or on top of existing therapies. The Phase 3 program will consist of two trials: a 6-month study aimed at confirming buntanetap’s symptomatic benefits and an…